Amazon One Medical starts GLP-1 program

GLP-1 weight-loss care is turning into a real primary-care business, not just a telehealth add-on. That is the big thing Amazon is betting on with One Medical’s new GLP-1 program. The pitch is simple: screening, prescribing, follow-ups, renewals, and pharmacy delivery in one system, instead of bouncing between a startup app, an outside doctor, and a separate pharmacy. Amazon rolled it out through One Medical on April 21, with both virtual and in-person care tied to Amazon Pharmacy. (cnbc.com) ### What actually launched? One Medical now has a dedicated GLP-1 weight-loss pathway inside its U.S. care offering. Patients can answer intake questions, meet a licensed provider, get assessed for eligibility, and, if prescribed, start treatment with ongoing follow-ups. Amazon is framing this as structured long-term management, not a one-time script. The service page leans hard on “dedicated provider,” “ongoing support,” and prescription management over time. (health.amazon.com) ### Why is Amazon doing this now? Because GLP-1s have exposed a messy part of healthcare that Amazon already knows how to attack — access and logistics. These drugs are popular, expensive, often require prior authorization, and work best when patients stay on them and adjust care over time. That makes the category perfect for a company that owns a pharmacy, a telehealth front door, and a membership-based primary-care network. Amazon is basically saying the hard part is not just getting a prescription — it is keeping the whole care loop running. (health.amazon.com) ### What does the program include? Three pieces matter. First, clinical screening and treatment selection through One Medical providers. Second, refill and renewal support, including quick on-demand consults. Third, pharmacy fulfillment through Amazon Pharmacy, with home delivery and pricing shown upfront. Amazon says insured patients can pay as little as $25 per month for some GLP-1 drugs, while cash-pay oral options start at $149 per month and injectables like Wegovy and Zepbound start at $299 per month. On-demand renewals start at $29 for message-based care and $49 for video. (cnbc.com) ### Is this just another telehealth weight-loss clinic? Not really — and that is why investors noticed. A lot of GLP-1 offerings in the market are built like narrow funnels: acquire a patient online, write the prescription, and keep the refill cycle going. Amazon’s version is trying to look more like ordinary healthcare. It combines same- or next-day primary care, ongoing chronic-condition support, virtual visits, and pharmacy delivery. That makes obesity treatment one service inside a broader care relationship, which is a stronger retention model if it works. (cnbc.com) ### Why did Hims & Hers stock react? Because Amazon entering any consumer-health lane changes the math. CNBC noted that shares of Hims & Hers and other obesity-linked names fell after the launch as investors started pricing in tougher competition. The concern is not that Amazon invented a cheaper drug. It is that Amazon can bundle discovery, prescribing, renewals, fulfillment, and Prime-linked convenience in a way smaller telehealth players cannot easily match. (cnbc.com) ### What is the catch? Amazon still does not control the hardest variable — drug supply and insurance coverage. GLP-1 care gets messy when plans deny coverage, prior authorizations drag on, or branded drugs go in and out of availability. Amazon can smooth the consumer experience, but it cannot fully remove those bottlenecks. And cash-pay prices, while competitive, are not a mass-market breakthrough. (cnbc.com) ### Why does this matter beyond Amazon? Because it pushes the market toward integrated obesity care. If Amazon can make GLP-1 treatment feel like a normal chronic-care workflow, rivals will have to offer more than quick prescribing and glossy apps. The category is maturing. The winner may be the company that keeps patients on treatment, handles the paperwork, and delivers the drug on time — not just the company that acquires them first. (cnbc.com) ### Bottom line Amazon is not just selling access to weight-loss drugs. It is trying to turn GLP-1s into a sticky, full-stack healthcare service. If that lands, the pressure will fall hardest on telehealth players that built their business around the prescription rather than the whole care journey. (cnbc.com)